Open AccessStudy Sets Response Benchmarks for FLT3‐Inhibitor Sequencing in FLT3 ‐Mutated AML
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13648
Subject(s) - medicine , myeloid leukemia , fms like tyrosine kinase 3 , leukemia , cancer research , myeloid , oncology , mutation , immunology , gene , genetics , biology
A new study of sequential exposure to FLT3 inhibitors demonstrates the benefits of these therapies across multiple lines and treatment settings for patients with FLT3 ‐mutated acute myeloid leukemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom